Lonza Shows Flexibility with Ibex® Design Platform to Accommodate tRNA Synthetase-Derived mAbs

aTyr Pharma is a clinical stage biotech focused on translating findings from a proprietary tRNA synthetase platform to develop first-in-class therapeutics to treat fibrosis and inflammation, and monoclonal antibodies targeting solid tumor cancers and autoimmune disease. With a robust pipeline, aTyr has experience working with several large, global contract manufacturers. Dr. Andrea Cubitt, VP of External Scientific Alliances and IP, explains aTyr’s selection of Lonza as CDMO for its lead mAb candidate, and subsequent experience with its Ibex® Design program, which dispelled preconceived views about Lonza’s suitability for smaller biotechs.